Mutations within protein kinase R-binding domain of NS5A protein of hepatitis C virus (HCV) and specificity of HCV antibodies in pretreament sera of HCV-chronically infected patients and their effect on the result of treatment

Japanese Journal of Infectious Diseases

Volumn 59, Issue 2, 2006, Pages 92-99

  Kmieciak, Dariusz ^a   Kruszyna, Lukasz ^a   Migdalski, Paweł ^a   Łaciński, Mariusz ^a   Juszczyk, Jacek ^a   Trzeciak, Wiesław H ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN E2; HEPATITIS C ANTIBODY; HEPATITIS C ANTIGEN; PEGINTERFERON ALPHA2A; PROTEIN KINASE R; RIBAVIRIN; VIRUS PROTEIN; VIRUS RNA;

ADULT; ANTIBODY SPECIFICITY; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DRUG RESPONSE; FEMALE; GENE MUTATION; GENE SEQUENCE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ALIGNMENT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; VIRUS LOAD;

ADULT; AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; IMMUNOENZYME TECHNIQUES; INTERFERON ALFA-2B; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; PILOT PROJECTS; PROGNOSIS; PROTEIN KINASES; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL NONSTRUCTURAL PROTEINS;

EID: 33646180828     PISSN: 13446304     EISSN: 13446304     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Robert, G. G. and Johnson, Y. N. (1997): Hepatitis C virus, eight years old. Viral Hepatitis Rev., 3, 17-37.
2. Alter, M. J. (1997): Epidemiology of hepatitis C. Hepatology, 26, 62S-65S.
3. Poynard, T., Leroy, V, Cohard, M., Thevenot, T., Mathurin, P., Opolon, P. and Zarski, J. P. (1996): Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology, 24, 778-789.
4. Manns, M. P., McHutchinson, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., Goodman, Z. D., Koury, K., Ling, M. and Albrecht, J. K. (2001): Peginterferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet, 358, 958-965.
5. Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Goncales, F. L., Haussinger, D., Diago, M., Carosi, G., Dhumeaux, D., Craxi, A., Lin, A., Hoffman, J. and Yu, J. (2002): Peginterferon alfa-2a plus ribavirin for chronic hepatitis C infection. N. Engl. J. Med., 347, 975-982.
6. Simmonds, P., Holmes, E. C., Cha, T.-A., Chan, S.-W., McOmish, F., Irvine, B., Beall, E., Yap, P. L., Kolberg, J. and Urdea, M. S. (1993): Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J. Gen. Virol., 74, 2391-2399.
7. Holland, J. J., De La Torre, J. C. and Steinhauer, D. A. (1992): RNA virus populations as quasispecies. Curr. Top. Microbiol. Immunol., 176, 1-20.
8. Weiner, A. J., Geysen, H. M., Christopherson, C., Hall, J. E., Mason, T. J., Saracco, G., Bonino, F., Crawford, K., Marion, C. D., Crawford, K. A., Brunetto, M., Barr, P. J., Miyamura, T., McHutchinson, J. and Houghton, M. (1992): Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc. Natl. Acad. Sci. USA, 89, 3468-3472.
9. Farci, P., Shimoda, A., Coiana, A., Diaz, G., Peddis, G., Melpolder, J. C., Strazzera, A., Chien, D. Y., Munoz, S. J., Balestrieri, A., Purcell, R. H. and Alter, H. J. (2000): The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science, 288, 339-344.
10. Mondelli, M. U., Cerino, A., Segagni, L., Meola, A., Cividini, A., Silini, E. and Nicosia, A. (2001): Hypervariable region 1 of hepatitis C virus: immunological decoy or biologically relevant domain? Antiviral Res., 52, 153-159.
11. Fernandez, J., Taylor, D., Morhardt, D. R., Mihalik, K., Puig, M., Rice, C. M., Feinstone, S. M. and Major, M. E. (2004): Long-term persistence of infection in chimpanzees inoculated with an infectious hepatitis C virus clone is associated with a decrease in the viral amino acid substitution rate and low levels of heterogeneity. J. Virol., 78, 9782-9789.
12. Kato, N., Ootsuyama, Y., Sekiya, H., Ohkoshi, S., Nakazawa, T., Hijikata, M. and Shimotohno, K. (1994): Genetic drift in hypervariable region 1 of the viral genome in persistent hepatitis C virus infection. J. Virol., 68, 4776-4784.
13. Heo, T.-H., Chang, J.-H., Lee, J.-W., Foung, S. K. H., Dubuisson, J. and Kang, C.-Y. (2004): Incomplete humoral immunity against hepatitis C virus is linked with distinct recognition of putative multiple receptors by E2 envelope glycoprotein. J. Immunol., 173, 446-455.
14. Blight, K. J., Kolykhalov, A. A. and Rice, C. M. (2000): Efficient initiation of HCV replication in cell culture. Science, 290, 1972-1974.
15. Moradpour, D., Evans, M. J., Gosert, R., Yuan, Z., Blum, H. E., Goff, S. P., Lindebach, B. D. and Rice, C. M. (2004): Insertion of green fluorescent protein into nonstructural protein 5A allows direct visualization of functional hepatitis C virus replication complexes. J. Virol., 78, 7400-7409.
16. Gale, M., Jr., Korth, M. J., Tang, N. M., Tan, S. L., Hopkins, D. A., Dever, T. E., Polyak, S. J., Gretch, D. R. and Katze, M. G. (1997): Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology, 230, 217-227.
17. He, Y., Tan, S.-L., Tareen, S. U., Vijaysri, S., Langland, J. O., Jacobs, B. L. and Katze, M. G. (2001): Regulation of mRNA translation and cellular signaling by hepatitis C virus nonstructural protein NS5A. J. Virol., 75, 5090-5098.
18. Enomoto, N., Sakuma, I., Asahina, Y., Kurosaki, M., Murakami, T., Yamamoto, C., Izumi, M., Marumo, F. and Sato, C. (1995): Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitution in the NS5a region. J. Clin. Invest., 96, 224-230.
19. Gale, M., Blakely, C. M., Kwieciszewski, B., Tan, S. L., Dosset, M., Tang, N. M., Korth, M. J., Polyak, S. J., Gretch, D. R. and Katze, M. G. (1998): Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol. Cell. Biol., 18, 5208-5218.
20. Enomoto, N., Sakuma, I., Asahina, Y., Kurosaki, M., Murakami, T., Yamamoto, C., Ogura, Y., Izumi, N., Maruno, F. and Sato, C. (1996): Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N. Engl. J. Med., 334, 77-81.
21. Magrin, S., Fabiano, C., Gianguzza, F., Cutrera, M., Alaimo, G. and Pagliaro, L. (1998): HCV NS5A mutations in Europeans infected by genotype lb. Gastroenterology, 115, 244-245.
22. Murashima, S., Ide, T., Miyajima, I., Kumashiro, R., Ueno, T., Sakisaka, S. and Sata, M. (1999): Mutations in the NS5A gene predict response to interferon therapy in Japanese patients with chronic hepatitis C and cirrhosis. Scand. J. Infect. Dis., 31, 27-32.
23. Yoshioka, K., Kobayashi, M., Orito, E., Watanabe, K., Yano, M., Sameshima, Y., Kusakabe, A., Hirofuji, H., Fuji, A., Kuriki, J., Arao, M., Murase, K., Mizokami, M. and Kakumu, S. (2001): Biochemical response to interferon therapy correlates with interferon sensitivity-determining region in hepatitis C virus genotype 1b infection. J. Viral Hepatitis, 8, 421-429.
24. Puig-Basagoiti, F., Saiz, J. C., Forns, X., Ampurdanes, S., Gimenez-Barcons, M., Franco, S., Sanchez-Fueyo, A., Costa, J., Sanchez-Tapias, J. M. and Rodes, J. (2001): Influence of the genetic heterogeneity of the ISDR and PePHD regions of hepatitis C virus on the response to interferon therapy in chronic hepatitis C. J. Med. Virol., 65, 35-44.
25. Herion, D. and Hoofnagle, J. H. (1997): The interferon sensitivity determining region: all hepatitis C virus isolates are not the same. Hepatology, 25, 769-771.
26. Khorsi, H., Castelain, S., Wyseur, A., Izopet, J., Canva, V., Rombout, A., Capron, D., Capron, J. P., Lunel, F., Stuyver, L. and Duverlie, G. (1997): Mutations of hepatitis C virus 1b NS5A 2209-2248 amino acid sequence do not predict the response to recombinant interferonalfa therapy in French patients. J. Hepatol., 27, 72-77.
27. Squadrito, G., Leone, F., Sartori, M., Nalpas, B., Berthelot, P., Raimondo, G., Pol, S. and Brechot, C. (1997): Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C virus to interferon alfa. Gastroenterology, 113, 567-572.
28. Zeuzem, S., Lee, J. H. and Roth, W. K. (1997): Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa. Hepatology, 25, 740-744.
29. Rispeter, K., Lu, M., Zibert, A., Wiese, M., Mandes de Oliveira, J. and Roggendorf, M. (1998): The "interferon sensitivity determining region" of hepatitis C virus is a stable sequence element. J. Hepatol., 29, 352-361.
30. Pawlotsky, J. M., Germanidis, G., Neumann, A. U., Pellerin, M., Frainais, P. O. and Dhumeaux, D. (1998): Interferon resistance of hepatitis C virus genotype 1b: relation to nonstructural 5A gene quasispecies mutations. J. Virol., 72, 2795-2805.
31. Nousbam, J.-B., Polyak, S. J., Ray, S. C., Sullivan, D. G., Larson, A. M., Carithers, R. L., Jr. and Gretch, D. R. (2000): Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy. J. Virol., 74, 9028-9038.
32. Aslan, N., Bozdayi, A. M., Cetinkaya, H., Sarioglu, M., Turkay, C., Bozkaya, H., Karayalcin, S., Yurtaydin, C. and Uzunalimoglu, O. (2004): The mutations in ISDR of NS5A gene are not associated with response to interferon treatment in Turkish patients with chronic hepatitis C virus genotype 1b infection. Turk. J. Gastroenterol., 15, 21-26.
33. Nakano, I., Fukuda, Y., Katano, Y., Toyoda, H., Hayashi, K., Kumada, T. and Nakano, S. (2004): Mutations of the interferon sensitivity-determining region (ISDR) correlate with the complexity of hypervariable region (HVR)-1 in the Japanese variant of hepatitis C virus (HCV) type 1b. J. Med. Virol., 74, 54-61.
34. Pascu, M., Martus, P., Hohne, M., Wiedenmann, B., Hopf, U., Schreier, E. and Berg, T. (2004): Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences. Gut, 53, 1345-1351.
35. Sarrazin, C., Berg, T., Lee, J. H., Ruster, B., Kronenberger, B., Roth, W. K. and Zeuzem, S. (2000): Mutations in the protein kinase-binding domain of the NS5A protein in patients infected with hepatitis C virus type 1a are associated with treatment response. J. Infect. Dis., 181, 432-441.
36. Duverlie, G., Khorsi, H., Castelain, S., Jaillon, O., Izopet, J., Lunel, F., Eb, F., Penin, F. and Wychowski, C. (1998): Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity. J. Gen. Virol., 79, 1373-1381.
37. Sarrazin, C., Herrmann, E., Bruch, K. and Zeuzem, S. (2002): Hepatitis C virus nonstructural 5A protein and interferon resistance: a new model for testing the reliability of mutational analyses. J. Virol., 76, 11079-11090.
38. Chomczynski, P. and Sacchi, N. (1987): Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem., 162, 156-159.
39. Kato, N., Hijikata, M., Ootsuyama, Y., Nakagawa, M., Ohkoshi, S., Sugimura, T. and Shimotohno, K. (1990): Molecular cloning of the patients with non-A, non-B hepatitis. Proc. Natl. Acad. Sci. USA, 87, 9524-9528.
40. Buti, M., Mendez, C., Schaper, M., Sauleda, S., Valdes, A., Rodrigo-Frias, F., Jardi, R. and Esteban, R. (2004): Hepatitis C virus core antigen as a predictor of non-response in genotype 1 chronic hepatitis C patients treated with peginterferon α-2b plus ribavirin. J. Hepatol., 40, 527-532.
41. Pradat, P., Maynard, M., Buti, M., Berthillon, P., Picchio, G., Tillman, H. L., Wiegand, J., Voirin, N., Manns, M. P., Esteban, J.-I., Martinot, M., Marcellin, P. and Trepo, C. (2004): The predictive value of core antigen testing for the management of hepatitis C patients receiving pegylated intereferon/ribavirin treatment. J. Med. Virol., 73, 392-396.
42. Choo, Q. L., Richman, K. H., Han, J. H., Berger, K., Lee, C., Dong, C., Gallegos, C., Coit, D., Medina, S. R. and Barr, P. J. (1991): Genetic organization and diversity of the hepatitis C virus. Proc. Natl. Acad. Sci. USA, 88, 2451-2455.
43. Lee, S. S., Heathcote, E. J., Reddy, K. R., Zeuzem, S., Fried, M. W., Wright, T. L., Pockros, P. J., Haussinger, D., Smith, C. I., Lin, A. and Pappas, S. C. (2002): Prognostic factors and early predictability of sustained viral response with peginterferon α-2a (40 kDa). J. Hepatol., 37, 500-506.
44. Chambers, T. J., Fan, X., Droll, D. A., Hembrador, E., Slater, T., Nickells, M. W., Dustin, L. B. and DiBisceglie, A. M. (2005): Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection. J. Virol., 79, 3071-3083.
45. Cormier, E. G., Tsamis, F., Kajumo, F., Durso, R. J., Gardner, J. P. and Dragic, T. (2004): CD81 is an entry coreceptor for hepatitis C virus. Proc. Natl. Acad. Sci. USA, 101, 7270-7274.
46. Ishii, K., Rosa, D., Watanabe, Y., Katayama, T., Harada, H., Wyatt, C., Kiyosawa, K., Aizaki, H., Matsuura, Y., Houghton, M., Abrignani, S. and Miyamura, T. (1998): High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C. Hepatology, 28, 1117-1120.
47. Kmieciak, D., Biernacka-Łukanty, J., Migdalski, P., Turek-Plewa, J., Wierzbicki, A., Juszczyk, J. and Trzeciak, W. H. (2005): A correlation between the heterogeneity of hypervariable region 1 of E2 glycoprotein of hepatitis C virus (HCV) and HCV antibody profile: a case study. Acta Virol., 49, 97-103.
48. Liang, T. J., Rehermann, B., Seeff, L. B. and Hoofnagle, J. H. (2000): Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann. Intern. Med., 132, 296-305.
49. Baumert, T. F., Wellnitz, S., Aono, S., Satoi, J., Herion, D., Tilman Gerlach, J., Pape, G. R., Lau, J. Y., Hoofnagle, J. H., Blum, H. E. and Liang, T. J. (2000): Antibodies against hepatitis C virus-like particles and viral clearance in acute and chronic hepatitis C. Hepatology, 32, 610-617.
50. Chu, C. M., Sheen, I. S. and Liaw, Y. F. (2004): Sequential changes of hepatitis C virus antibody profiles during treatment of chronic hepatitis C of genotype 1b: pretreatment antibody response to E2/NS1 correlated sustained response. Infection, 32, 153-156.
51. Zampino, R., Marrone, A., Mangoni, E. D., Santarpia, L., Sica, A., Tripodi, M.F., Utili, R., Ruggiero, G. and Adinolfi, L. E. (2004): Anti-envelope 1 and 2 immune response in chronic hepatitis C patients: effects of hepatitis B virus coinfection and interferon treatment. J. Med. Virol., 73, 33-37.